Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14898386 | 0.98 | GBA1 (0.62) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL10078112 | 0.98 | GBA1 (0.62) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL3536027 | 0.94 | CYP19A1 (0.56) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL460417 | 0.93 | HRH4 (0.65) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL18462060 | 0.93 | GBA1 (0.62) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL24675720 | 0.91 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL9926319 | 0.91 | GBA1 (0.64) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL15944228 | 0.91 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL21959579 | 0.91 | HRH4 (0.66) | GBA1HRH4HRH3CYP19A1EPHX2 | |
| SCHEMBL14681055 | 0.91 | GBA1 (0.64) | GBA1HRH4HRH3CYP19A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021003050-A2 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020142102-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020132588-A1 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | KLEO PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | GBA1 4570/4885HRH4 1806/4885HRH3 1158/4885 |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GBA1 669/4885HRH4 1851/4885HRH3 2016/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | GBA1 280/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | GBA1 1017/4885HRH4 4083/4885HRH3 3193/4885 |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GBA1 669/4885HRH4 1851/4885HRH3 2016/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GBA1 2752/4885HRH4 4334/4885HRH3 3879/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GBA1 669/4885HRH4 1851/4885HRH3 2016/4885 |
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | TP53, TP53BP1, MDM2 | GBA1 2460/4885HRH4 4471/4885HRH3 4541/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | GBA1 280/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | GBA1 946/4885HRH4 4246/4885HRH3 3700/4885 |
| US-10543255-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | APLNR, SCTR, GIPR | GBA1 1277/4885HRH4 1253/4885HRH3 1725/4885 |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | GBA1 1518/4885HRH4 4345/4885HRH3 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.